EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONAL PROFILE IN LUNG CANCER - MOROCCAN COHORT

Authors

  • Houda KAANANE Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca 20250, Morocco
  • Hicham EL ATTAR Laboratory of Anathomo-pathology Moulay Idriss 1er, Casablanca 20250, Morocco
  • Amal LOUAHABBI Laboratory of Biology Sebta, Casablanca 20250, Morocco
  • IGOT CASA IGOT CASA IGOT (Inter Group of Thoracic Oncology), CHU Ibn Rochd, Casablanca 20250, Morocco
  • Hind BERRADI Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy,University Hassan II, Casablanca 20250, Morocco
  • Hind HASSANI IDRISSI Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca
  • Meriem KHYATTI Oncovirology Laboratory, Institut Pasteur du Maroc, Casablanca
  • Sellama NADIFI Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca

DOI:

https://doi.org/10.34874/IMIST.PRSM/fsejournal-v8i2.28056

Abstract

Background: Lung cancer constitutes the leading cause of cancer-associated mortality worldwide, with approximately 85% of lung cancer cases being non-small cell lung cancer (NSCLC) histological type. The study of epidermal growth factor receptor (EGFR) gene mutational profile in non-small cell lung cancer patients has a special clinical significance in the selection of patients for tyrosine-kinase inhibitor therapy. The aim of this study was to identify the frequency and spectrum of EGFR mutations in a cohort of Moroccan patients with lung cancer using the ADx- ARMS technology as routine method.

 Materials and methods: We performed this study by processing 164 cases of NSCLC patients recruited between 2015 and 2018. Using the DNA extracted from the formalin-fixed paraffin- embedded FFPE tissue, we evaluated EGFR mutations using HRM-PCR, real time PCR “ADx- ARMS technology for results confirmation.

 Results: The distribution of EGFR mutations in our cohort was as follows: 70% of patients having a deletion in exon 19, 10% in exon 21(L858R), 10% in exon 20 and 10% in exon 18 (G719X). Conclusion: These results shows the need to incorporate the EGFR mutation test into routine practice and to develop rapid technological approaches in our laboratories for the availability of effective targeted therapy.

 

Downloads

Published

02-02-2019

Issue

Section

Life Sciences (Medical, Health, Agriculture, Biology, Genetics)